RET and cancer: To test the effects of inhibiting Ret signaling on tumor cell viability, we treated 3 different cell lines (NB7, NB10, NB16) with the multi-kinase inhibitor Vandetanib (ZD6474), currently in human trials for other cancers [74,75], and measured cell viability using an MTS-based assay.